These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 34069315)

  • 1. Correction: Kim et al. Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy.
    Kim JW; Cho YB; Lee S
    Cells; 2021 May; 10(5):. PubMed ID: 34069315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
    Gallerne C; Prola A; Lemaire C
    Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
    Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
    Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
    Li HK; Matsumoto Y; Furusawa Y; Kamada T
    J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
    Kale Ş; Korcum AF; Dündar E; Erin N
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):253-262. PubMed ID: 31522240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Based Targeting of Cell Surface GRP94 Specifically Inhibits Cetuximab-Resistant Colorectal Cancer Growth.
    Jeoung MH; Kim TK; Kim JW; Cho YB; Na HJ; Yoo BC; Shim H; Song DK; Heo K; Lee S
    Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31683810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
    Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
    Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.
    Speranza G; Anderson L; Chen AP; Do K; Eugeni M; Weil M; Rubinstein L; Majerova E; Collins J; Horneffer Y; Juwara L; Zlott J; Bishop R; Conley BA; Streicher H; Tomaszewski J; Doroshow JH; Kummar S
    Invest New Drugs; 2018 Apr; 36(2):230-239. PubMed ID: 28808818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line.
    Graner AN; Hellwinkel JE; Lencioni AM; Madsen HJ; Harland TA; Marchando P; Nguyen GJ; Wang M; Russell LM; Bemis LT; Anchordoquy TJ; Graner MW
    Int J Hyperthermia; 2017 May; 33(3):303-317. PubMed ID: 27829290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.
    Taldone T; Zatorska D; Ochiana SO; Smith-Jones P; Koziorowski J; Dunphy MP; Zanzonico P; Bolaender A; Lewis JS; Larson SM; Chiosis G; Pillarsetty NV
    J Labelled Comp Radiopharm; 2016 Mar; 59(3):129-32. PubMed ID: 26806023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.
    Deribe YL; Sun Y; Terranova C; Khan F; Martinez-Ledesma J; Gay J; Gao G; Mullinax RA; Khor T; Feng N; Lin YH; Wu CC; Reyes C; Peng Q; Robinson F; Inoue A; Kochat V; Liu CG; Asara JM; Moran C; Muller F; Wang J; Fang B; Papadimitrakopoulou V; Wistuba II; Rai K; Marszalek J; Futreal PA
    Nat Med; 2018 Oct; 24(10):1627. PubMed ID: 30104769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retracted: Molecular characterization of excipients' preferential interactions with therapeutic monoclonal antibodies.
    Kim J; Krebs MRH; Trout BL
    J Pharm Pharmacol; 2018 Feb; 70(2):289-304. PubMed ID: 28776673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy.
    Bryant KG; Chae YC; Martinez RL; Gordon JC; Elokely KM; Kossenkov AV; Grant S; Childers WE; Abou-Gharbia M; Altieri DC
    Oncotarget; 2017 Dec; 8(68):112184-112198. PubMed ID: 29348817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction.
    Trendowski M
    Pharmacol Res; 2015 Sep; 99():202-16. PubMed ID: 26117427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: Kim et al. Effects of Nursing Simulation Using Mixed Reality: A Scoping Review.
    Kim KJ; Choi MJ; Kim KJ
    Healthcare (Basel); 2021 Nov; 9(12):. PubMed ID: 34946494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
    Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
    Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
    Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
    Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of monoclonal antibody binding to estrogen and progesterone receptor content in breast cancer.
    Hendler FJ; Yuan D
    Cancer Res; 1985 Jan; 45(1):421-9. PubMed ID: 3965148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction: Kim, N.K., et al. Study of the Association between microRNA (miR-25T>C, miR-32C>A, miR-125C>T, and miR-222G>T) Polymorphisms and the Risk of Recurrent Pregnancy Loss in Korean Women.
    Lee JY; Kim JO; Park HS; Ryu CS; Kim JH; Kim YR; Lee WS; Lee JR; Kim NK
    Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32824525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resorcinol-Based Grp94-Selective Inhibitors.
    Khandelwal A; Crowley VM; Blagg BSJ
    ACS Med Chem Lett; 2017 Oct; 8(10):1013-1018. PubMed ID: 29057043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.